You are here: Industry Insights > Ampio

News List

Ampio reveals preliminary positive results on inhaled Ampion in Covid-19 respiratory distress pharmaceutical-technology
March 17, 2021
Ampio Pharmaceuticals has revealed preliminary positive results of its AP-014 Phase I clinical trial that involves using of inhaled Ampion in treating respiratory distress in patients due to Covid-19.
Ampio Announces Early Positive Data in Inhaled Ampion Trial for COVID-19 Respiratory Distress americanpharmaceuticalreview
February 02, 2021
Ampio Pharmaceuticals announced early positive data from its ongoing U.S. Phase I controlled, observer-blinded clinical trial of inhaled Ampion versus standard of care for patients with COVID-19 respiratory distress (AP-014).
Ampio Provides Update on Clinical Trials for COVID-19 Treatment americanpharmaceuticalreview
January 12, 2021
Ampio Pharmaceuticals announced an update on the launch of a new global clinical trial for intravenous (IV) treatment of COVID-19 with Ampion and provided updates on its ongoing U.S. trial for inhalation treatment of COVID-19.
Ampio Provides Update on Clinical Trials for Ampion™ Treatment of COVID-19 Patients prnewswire
January 05, 2021
Ampio Pharmaceuticals, Inc. announced an update on the launch of a new global clinical trial for intravenous ("IV") treatment of COVID-19 with Ampion and provided updates on its ongoing U.S. trial for inhalation treatment of COVID-19.
Inhaled Ampion Advances to Second Group of COVID-19 Patients with Respiratory Distress americanpharmaceuticalreview
November 23, 2020
Ampio Pharmaceuticals announced the second group in the Phase I inhaled Ampion™ clinical study is being treated following clearance by the Safety Monitoring Committee (SMC) who found Ampion to be safe and well-tolerated after reviewing the results from ..
Ampio Begins Phase 1 Clinical Trial of Inhaled Ampion For COVID-19 Patients With Respiratory Distress prnewswire
October 29, 2020
Ampio Pharmaceuticals, Inc., a biopharmaceutical company focused on the advancement of immunology based therapies for prevalent inflammatory conditions, announced the Company has begun recruiting and enrolling patients in ...
Ampio announces enrolment completion for intravenous Covid-19 clinical trial pharmaceutical-business-review
September 18, 2020
Ampio Pharmaceuticals, a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions announces the following ...
Ampio Reports Positive Results for Ampion Treatment in COVID-19 Patients americanpharmaceuticalreview
September 15, 2020
Ampio Pharmaceuticals announced positive results in early trial for intravenous (IV) Ampion treatment for COVID-19 patients.
Ampio Provides Update on COVID-19 Clinical Trial Activities prnewswire
August 20, 2020
Ampio Pharmaceuticals, Inc., a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, provides updates regarding the following clinical trials.
Ampio Starts Patient Enrollment in Ampion COVID-19 Program americanpharmaceuticalreview
July 30, 2020
Ampio Pharmaceuticals is actively working on the development of therapies for patients infected with the SARS-CoV-2 virus (COVID-19).

Previous page 1 2 Next page